A prospective study exploring the safety and efficacy of lenvatinib for patients with advanced hepatocellular carcinoma and high tumor burden: The LAUNCH study.

Kazufumi Kobayashi Sadahisa Ogasawara Susumu Maruta Tomomi Okubo Norio Itokawa Yuki Haga Yuya Seko Michihisa Moriguchi Shunji Watanabe Yuki Shiko Hirokazu Takatsuka Hiroaki Kanzaki Keisuke Koroki Masanori Inoue Masato Nakamura Soichiro Kiyono Naoya Kanogawa Takayuki Kondo Eiichiro Suzuki Yoshihiko Ooka Shingo Nakamoto Yosuke Inaba Masafumi Ikeda Shinichiro Okabe Naoki Morimoto Yoshito Itoh Kazuyoshi Nakamura Kenji Ito Ryosaku Azemoto Masanori Atsukawa Ei Itobayashi Naoya Kato

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)

Lenvatinib is safe and effective for advanced HCC in patients with Child-Pugh A, even with high tumor burden. However, it carries a higher risk of AEs and may not provide adequate efficacy for patients with Child-Pugh B.

Keyphrases

mental health

risk factors